Pfizer Acquires Obesity Biotech Metsera, Enters GLP-1 War as Trump Medicare Coverage Launches

Challenging the Eli Lilly–Novo Nordisk duopoly… GLP-1 market poised for explosion as Trump Medicare coverage kicks in July

Pfizer (PFE) announced it will acquire obesity biotech Metsera for billions of dollars, signaling a serious entry into the GLP-1 obesity treatment market dominated by Eli Lilly (LLY) and Novo Nordisk (NVO).

The timing is impeccable. President Trump has announced that Medicare will cover GLP-1 obesity drugs with a $50 monthly patient copay starting July 1st. Pfizer is entering the market just as millions of eligible patients gain access.

How large is the GLP-1 market now?

GLP-1 obesity drugs—represented by Ozempic, Wegovy, and Zepbound—are already the fastest-growing pharmaceutical category in history. Current monthly market value is approximately $1,000–$1,350 per patient. If the Trump administration reduces the government acquisition cost to $245 and patient copay to $50, the addressable patient population will explode.

Goldman Sachs estimates the GLP-1 market will exceed $100 billion by 2030. Eli Lilly and Novo Nordisk currently control the vast majority. Pfizer is now targeting a piece of this pie.

Pfizer's two-pronged strategy

Pfizer is attacking the GLP-1 market from two directions.

First is orforglipron, an oral GLP-1 already in development. Unlike Wegovy and Zepbound, which are injectables, this is a daily pill. The absence of daily injections is expected to improve patient adherence significantly. Pfizer's internal clinical data is also proving positive.

Second is the Metsera acquisition. Metsera is a startup developing next-generation GLP-1 molecules with potentially superior efficacy or improved safety profiles compared to existing drugs. Pfizer is layering Metsera's mid-to-long-term pipeline on top of orforglipron as a near-term asset.

Reports suggest orforglipron will be included in the Trump administration's expanded Medicare coverage list. Once FDA-approved, it could plug directly into government procurement channels.

Why catching up isn't easy

Pfizer's GLP-1 entry isn't universally bullish.

Eli Lilly has locked down the market with Zepbound and Mounjaro and has an oral GLP-1 in more advanced clinical trials than orforglipron. Novo Nordisk has hundreds of millions of patients on Wegovy and Ozempic, leveraging established brand power. Closing a multi-year market lead built by these two giants in a short timeframe is formidable.

As Covid tailwinds fade, Pfizer faces declining sales from Paxlovid (-62%) and Covid vaccines (-59%), making new growth engines urgent. While obesity drugs offer promise, major blockbuster patents expire in 2027–2028. For Pfizer, GLP-1 is less a choice and more a survival imperative.

Q1 results delivered an earnings beat

The Q1 results released alongside the Metsera announcement were solid. Revenue of $14.45 billion beat consensus ($13.82 billion). The collapse of Covid products was offset by new drug growth: Eliquis (+13%), Vyndaqel (+39%), RSV vaccine (+37%). New and acquired products grew 22% on an operational basis. Full-year guidance ($59.5B–$62.5B revenue, $2.80–$3.00 adjusted EPS) was maintained.